21 Week, 2025: ai targets cellular zombies and xprize offers 101 million to reverse aging effects

AI-powered senescent cell clearance is emerging as a game changer in longevity medicine by selectively eliminating aging cells that drive inflammation and tissue decline, enabling precise, scalable therapies that could extend healthy lifespan.

AI Aids Cellular Senescence Targeting for Longevity

Researchers at BioVita, in collaboration with AI teams at DeepMind, employ machine learning algorithms to identify and target senescent cells – often dubbed 'cellular zombies' – in preclinical models. By using AI-driven analysis of gene expression profiles, they selectively eliminate these cells, reducing systemic inflammation and mitigating key hallmarks of aging. This approach could pave the way for novel longevity therapeutics by enhancing tissue regeneration and delaying age-associated diseases.

Key points:

• Machine learning algorithms analyze gene expression and phenotypic markers to identify senescent cell populations.
• AI-driven high-throughput screening guides development of targeted senolytic compounds.
• Preclinical application in murine models demonstrates reduced SASP inflammation and improved tissue regeneration.

Why it matters: This AI-enabled senescent cell clearance approach could revolutionize longevity medicine by offering precise, scalable interventions against age-related pathologies.

Full article →

XPrize Launches $101M Challenge to Reverse Aging Effects

XPrize Healthspan convenes a global competition to reinvigorate aging biology, offering $101 million to teams that demonstrate a ten-year reversal in muscle mass, cognitive function, and immune response among 50- to 80-year-olds. Entrants are evaluated for scientific rigor, scalability, and affordability, with finalists gearing up for a one-year clinical validation, aiming to democratize accessible longevity interventions.

Key points:

• $101 million XPrize incentivizes ten-year reversal of sarcopenia, cognitive decline, and immunosenescence
• Interventions include repurposed drugs (metformin, rapamycin), NMN/NAD+ augmentation, neuromodulation, and lifestyle regimens
• Finalists undergo an $81 million, one-year clinical validation focusing on scalability, affordability, and robust biomarker outcomes

Why it matters: By funding scalable aging reversal strategies targeting fundamental biology, this prize could transform healthcare by extending healthspan and reducing age-related disease burden.

Full article →

Personalized Longevity Testing Reveals 7.5-Year Youthful Biological Age

The Longevity Doctor clinic, led by anti-ageing specialist Dr Philip Borg, conducts over 150 biomarker assays, a Trudiagnostic Biological Age test, DEXA scans and VO₂ max evaluation. Integrating metabolic monitoring, body composition and fitness profiling, the clinic formulates personalized preventive and training protocols to optimize healthspan and mitigate age-related risks.

Key points:

• Over 150 blood biomarkers and a Trudiagnostic Biological Age assay quantify cellular ageing relative to chronological age.
• Continuous glucose monitoring and VO₂ max testing evaluate metabolic and cardiovascular fitness for personalized health profiling.
• Full-body DEXA scans and ultrasound screenings assess organ health and bone density, guiding targeted resistance training to improve muscle mass and longevity.

Why it matters: Data-driven longevity assessments create a paradigm shift toward preventive, personalized health interventions that slow biological ageing and reduce disease burden.

Full article →

Longevity Investments Surge to $8.5B in 2024

Analysts at Longevity.Technology publish the 2024 Annual Longevity Investment Report, detailing USD 8.49 billion invested across 331 transactions. They segment funding by technology domain, investment stage, and geography to uncover trends in senotherapeutics, discovery platforms, and consumer applications driving healthspan extension.

Key points:

• Report quantifies USD 8.49 billion funding across 331 deals, marking a 220% increase from 2023.
• Segmentation across 25 domains highlights over USD 2 billion for discovery platforms and significant investment in senotherapeutics.
• U.S. firms represent 57% of companies and 84% of deal volume, with later-stage VC comprising 31% of total funding.

Why it matters: This financial rebound underscores maturing longevity biotech, catalyzing resource allocation toward foundational discovery platforms and accelerating translational therapies.

Full article →

Longevity Medicine Gains Traction, But Lifestyle Sets the Pace

Biotech companies and research teams at Harvard and Columbia University are advancing longevity medicine through senolytic compounds and epigenetic reprogramming, targeting aged cells to potentially reverse cellular damage. Using clinical assays—such as blood biomarker profiling and fitness assessments—they evaluate treatment efficacy. However, experts emphasise that fundamental lifestyle factors—nutrition, physical activity and sleep hygiene—remain the cornerstone of effective lifespan and healthspan extension.

Key points:

• Senolytic drugs targeting Bcl-2 family proteins eliminate senescent cells in murine models, improving glucose tolerance and physical endurance.
• Epigenetic reprogramming via transient Yamanaka factor expression restores youthful DNA methylation patterns, reducing epigenetic age acceleration in preclinical assays.
• Calorie restriction in the CALERIE trial yields a 2–3% decrease in biological age, as measured by multi-omic biomarker panels and reduced inflammatory cytokines.

Why it matters: Integrating cutting-edge longevity therapies with proven lifestyle interventions could revolutionise preventive healthcare by targeting ageing’s root causes rather than treating disease.

Full article →

mRNA Boosts Klotho to Extend Healthspan

The collaboration between biotech company Klothea Bio and Healthy Longevity Clinic leverages a proprietary mRNA platform to upregulate endogenous Klotho, an anti-aging protein. By delivering lipid-encapsulated mRNA instructions, they activate the body’s protein synthesis pathways. The approach aims to counteract age-associated inflammation, cognitive decline, and immune deterioration in adults.

Key points:

• mRNA-based Klotho delivery via lipid nanoparticles upregulates anti-aging protein expression.
• Collaboration recognized as Top 40 semifinalist in the $101 million XPRIZE Healthspan milestone competition.
• Preclinical data suggest improved cognition, reduced inflammation, and enhanced immune function in aging models.

Why it matters: Elevating Klotho via mRNA could revolutionize aging therapeutics by restoring cellular homeostasis and delaying multiple age-related disorders.

Full article →

Women Lead Biohacking Rebellion to Optimize Longevity

Independent reporter Holly Baxter profiles women who adopt advanced biohacking tools—from PEMF and intranasal red-light devices to personalised nutrition and monitoring—to optimise bone strength, sleep, and metabolic health and prepare for menopause.

Key points:

• Women integrate PEMF mats at home for inflammation reduction and cellular recovery, inspired by veterinary uses.
• Advanced biohacking tech like NanoVi oxygen delivery, intranasal photobiomodulation, and LYMA lasers support brain, skin, and hair protocols.
• Biomarker tracking via Oura rings and bioelectrical impedance scales guides personalized nutrition, exercise, and hormone-cycle-based therapies.

Full article →